AUG 7·SEC EDGARLow
Prange Karen sold $138K of ATRC
Prange Karen sold 3,564 shares of AtriCure, Inc. (ATRC) at $38.80 ($0.14M total) on 2026-08-05.
StockNASDAQ · US · USDHealthcare · Medical Instruments & Supplies
$ATRC
AtriCure, Inc.
Price · $ATRCvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $ATRC in the last 7 days.
Top stories · $ATRCMore →
AUG 7·SEC EDGAR
Yuen Maggie sold $134K of ATRC
Yuen Maggie sold 3,500 shares of AtriCure, Inc. (ATRC) at $38.42 ($0.13M total) on 2026-08-05.
JUL 30·SEC EDGAR
Doraiswamy Vinayak sold $233K of ATRC
Doraiswamy Vinayak (Chief Scientific Officer) sold 6,000 shares of AtriCure, Inc. (ATRC) at $38.88 ($0.23M total) on 2026-07-28.
ATRC sentiment & insider activity
Recent ATRC coverage spans insider activity, financial news and earnings.
In the last 30 days, ATRC insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($1.7M). The most active reporter was Yuen Maggie with 1 filing.
What's driving ATRC
This is an insider sale disclosure, not a company fundamental update, but it can slightly affect near-term sentiment.
This is an insider open-market sale without a 10b5-1 plan disclosed, which can be read as mild negative sentiment but is not a fundamental catalyst.
This is a routine insider open-market sale with no 10b5-1 plan disclosed; it may slightly affect sentiment but is not a fundamental catalyst.
The filing discloses an insider sale, which can be read as mild near-term sentiment pressure but is not a fundamental catalyst by itself.
This is a routine insider open-market sale with no stated 10b5-1 plan, but it does not disclose new company fundamentals.
alphai scores every news story that mentions ATRC with an AI model for sentiment and relevance, and aggregates insider trades from AtriCure, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ATRC
Score
Prange Karen sold $138K of ATRC
Prange Karen sold 3,564 shares of AtriCure, Inc. (ATRC) at $38.80 ($0.14M total) on 2026-08-05.
2 min readYuen Maggie sold $134K of ATRC
Yuen Maggie sold 3,500 shares of AtriCure, Inc. (ATRC) at $38.42 ($0.13M total) on 2026-08-05.
1 min readDoraiswamy Vinayak sold $233K of ATRC
Doraiswamy Vinayak (Chief Scientific Officer) sold 6,000 shares of AtriCure, Inc. (ATRC) at $38.88 ($0.23M total) on 2026-07-28.
2 min readWEHRWEIN SVEN sold $946K of ATRC
WEHRWEIN SVEN sold 25,000 shares of AtriCure, Inc. (ATRC) at $37.84 ($0.95M total) on 2026-07-28.
1 min readNoznesky Justin J sold $240K of ATRC
Noznesky Justin J (Chief Mktg & Strategy Officer) sold 6,182 shares of AtriCure, Inc. (ATRC) at $38.80 ($0.24M total) on 2026-07-29.
2 min readAtriCure, Inc. (ATRC) Beat Earnings Estimates. Here’s What Could Drive ATRC Stock Next
AtriCure (NASDAQ:ATRC) reported Q2 FY26 revenue of $153.6M and adjusted EPS of $0.18 on July 23, topping consensus by $1.79M and $0.16. Net income was $9M versus a $6.2M loss a year earlier. Gross margin rose to 77.2%. Management guided FY2026 revenue $602M-$610M and raised adjusted EBITDA to ~$85M-$89M.
7 min readAtriCure, Inc. (ATRC): Results of Operations and Financial Condition
AtriCure, Inc. (ATRC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-7232026.htm EX-99.1 Document Exhibit 99.1 For immediate release July 23, 2026 AtriCure Reports Second Quarter 2026 Financial Results • Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year • Second Quarter 2026 profitabi
3 min read
(ATRC) and the Role of Price-Sensitive Allocations
Atricure Inc. (NASDAQ: ATRC) shows strong near-term sentiment with neutral mid and long-term outlooks, featuring a mid-channel oscillation pattern. AI models suggest specific institutional trading strategies, including long, breakout, and short positions, with an exceptional 65.4:1 risk-reward setup targeting a 19.5% gain versus 0.3% risk. The analysis provides multi-timeframe signal insights, including support and resistance levels for various holding periods.
4 min read
Insider Sell Alert: Karen Prange Sells 3,000 Shares of AtriCure Inc (ATRC)
Karen Prange, a Director at AtriCure Inc (ATRC), sold 3,000 shares of the company on May 20, 2026, reducing her holdings to 26,373 shares. This transaction follows a pattern of 12 insider sells and no insider buys for AtriCure over the past year. The stock is currently priced at $28.65, giving it a GuruFocus Value of $39.37, indicating it is modestly undervalued with a price-to-GF-Value ratio of 0.73.
3 min readEarnings Flash (ATRC) AtriCure, Inc. Reports Q1 Revenue $141.2M, vs. FactSet Est of $139.7M
AtriCure, Inc. (ATRC) announced Q1 revenue of $141.2 million, surpassing the FactSet estimate of $139.7 million. Additionally, the company reported Q1 adjusted EPS of $0.00 per share, outperforming FactSet's estimate of $-0.06. This positive financial performance indicates stronger-than-anticipated results for the medical equipment company.
2 min read